Within the cardiovascular space alone the forecasted economic burden on society for medical care is expected to rise substantially. Cell therapy offers the potential of alleviating much of the burdens of these chronic diseases in a cost-effective way.
- It is projected that by 2030, 43.9% of Americans – approximately 139 million people – will have some form of cardiovascular disease. Between 2012 and 2030, total direct medical costs of cardiovascular disease are projected to increase from $396 billion projected to $918 billion. Real indirect costs – due to lost productivity – for all forms of cardiovascular disease are estimated to increase more than 58% from $183 billion in 2012 to $290 billion in 2030. The combined costs are expected to increase to more than $1.48 trillion by 2030.
AMI (Heart Attack)
AMI patients, one of the target populations in our Ischemic Repair Program, are at significant risk of downstream adverse events including chronic heart failure, re-current AMI, significant arrhythmias, premature death or acute coronary syndrome. Treatment of these patients post-heart attack represents a significant financial burden for many managed care programs. We expect that this burden will increase as the “baby boomer” population ages. AMR-001, if approved for this subpopulation alone, could provide significant pharmacoeconomic benefits by preventing downstream cardiac adverse events.
- Acute myocardial infarctions (“AMI”) are the sixth most expensive condition treated in U.S. hospitals, with a national hospital bill of more than $37 billion annually.
Chronic Heart Failure
An additional and related potential application for AMR-001 includes chronic heart failure (CHF).
- Chronic heart failure affects 5.7 million individuals in the U.S. alone. Each year, nearly 1 million people are hospitalized with CHF, of whom 30 – 60 % are “readmits.” CHF is now a main or contributing cause of nearly 53,000 U.S. deaths each year.